Phase NA × Lymphoma, Follicular × Cyclophosphamide × Clear all Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
Phase NA Completed
10 enrolled 11 charts
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Phase NA Completed
10 enrolled
THALLO
Phase NA Terminated
10 enrolled 15 charts
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Phase NA Terminated
2 enrolled 11 charts
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
Phase NA Terminated
3 enrolled 6 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Phase NA Terminated
43 enrolled
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
Phase NA Completed
68 enrolled
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
Phase NA Terminated
16 enrolled 6 charts
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Phase NA Completed
40 enrolled 9 charts
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
Phase NA Terminated
6 enrolled 13 charts
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
Phase NA Unknown
35 enrolled
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Phase NA Terminated
4 enrolled
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
Phase NA Withdrawn